Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX TWISTHALER versus VALISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX TWISTHALER versus VALISONE.
ASMANEX TWISTHALER vs VALISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators (e.g., cytokines, chemokines, adhesion molecules) and suppression of inflammatory cell migration and activation in the airways.
Betamethasone valerate is a corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), which control the release of arachidonic acid from membrane phospholipids, thereby inhibiting prostaglandin and leukotriene synthesis. It has anti-inflammatory, antipruritic, and vasoconstrictive effects.
Inhalation: 1-2 inhalations twice daily (morning and evening). Typical adult dose: 200-400 mcg twice daily. Maximum: 800 mcg/day.
Topical: Apply a thin layer to affected skin once or twice daily. Maximum duration: 2 weeks.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation via ASMANEX TWISTHALER is approximately 5 hours (range 4–6 hours) in patients with asthma. This relatively short half-life supports twice-daily or once-daily dosing with sustained clinical effect due to prolonged local retention in the lungs.
Approximately 1.7 hours after topical application; systemic half-life is short due to rapid metabolism.
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver via CYP3A4. Unchanged drug and metabolites are excreted primarily in the feces via biliary elimination (approximately 74% of a single oral dose) and to a minor extent in the urine (approximately 8%). For inhaled doses, renal excretion of unchanged drug is negligible (<1% of administered dose).
Renal (primarily as metabolites, <5% unchanged); biliary/fecal elimination accounts for <10%.
Category C
Category C
Corticosteroid, Inhaled
Corticosteroid